Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Janes has a total of 334 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hemorrhagic Transformation Mediates Stress Hyperglycemia Effect on Functional Outcome in Minor Ischemic Stroke

    by Francesco Bax, Mariarosaria Valente, Federico Mazzacane, Matteo Foschi, Raffaele Ornello, Alessandro Marè, Francesco Toraldo, Caterina Del Regno, Roberto Sperotto, Antonio Taglialatela, et al.

    Background: Stress hyperglycemia (SHG) is associated with worse clinical outcomes in minor ischemic stroke. Hemorrhagic transformation (HT) represents a potential mechanism mediating this association, but clear characterization of this relationship is lacking. We therefore aimed to investigate whether HT mediates the effect of SHG on functional outcomes in patients with minor stroke. Methods: This was a prospective international cohort study (5 comprehensive stroke centers, Italy/United Kingdom). Individuals presenting with National Institutes of Health Stroke Scale ≤5, prestroke modified Rankin Scale ≤1, and without large vessel occlusion between January 2022 and December 2023 were included. SHG was assessed ≤24 hours using the glucose‐to‐glycated hemoglobin ratio. HT ≤7 days was classified in hemorrhagic infarction and parenchymal hematoma. Causal mediation was used to estimate SHG effect on modified Rankin Scale ≥2 at 3 months mediated by HT. Effect modification of age, diabetes, C‐reactive protein, and intravenous thrombolysis was explored. Results: There were 1316 patients included (mean age 69.6±12.7 years, 837 men [63.6%]). Higher glucose‐to‐glycated hemoglobin ratio quartiles were associated with modified Rankin Scale ≥2 (adjusted odds ratio [OR], 1.72 [95% CI, 1.24–2.40]; P =0.001) and HT severity (adjusted OR, 2.32 [95% CI, 1.43–3.76]; P =0.001). A significant proportion (14.8%) of the SHG effect on mRS was mediated by HT (average causal mediation effect, 0.014 [95% CI, 0.003–0.030]; P =0.006). Effect modification was found for younger age (≈60 years old), higher C‐reactive protein (≈7 mg/L), and absence of diabetes, but not for intravenous thrombolysis use. Conclusions: In patients with minor stroke, HT significantly mediated the effect of SHG on unfavorable outcome. The mediating effect of HT was greater in patients either ≈60 years old, without diabetes, or with high baseline C‐reactive protein levels. These initial results might inform patient selection for future interventional studies.


  • Open Access

    Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke: Rationale and Study Protocol of a Multicenter, Randomized, Proof-of-Concept, Phase 2a/b Trial in Patients Treated With Mechanical Thrombectomy (DOWN-SUITE)

    by Francesco Andrea Pedrazzini, Lorenzo Piergallini, Susanna Diamanti, Enrico Fainardi, Sergio Lucio Vinci, Caterina Sozzi, Matteo Farè, Emanuela Rossi, Francesca Graziano, Francesca Poggetti, et al.

    BACKGROUND: Collateral blood flow is a critical determinant of successful recanalization in acute ischemic stroke caused by large vessel occlusion. Head down tilt −15° (HDT15), similar to Trendelenburg positioning, is a simple, low-cost positional therapy that may augment cerebral collateral blood flow and penumbral survival. The aim of the study is to assess the safety, feasibility, and efficacy of HDT15 in improving cerebral collateral circulation and clinical outcomes in patients with large vessel occlusion–acute ischemic stroke treated with mechanical thrombectomy (MT). METHODS: The DOWN-SUITE trial (Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke) is a multicenter, randomized, open-label, phase 2a/b clinical trial with blinded outcome assessment, conducted across 7 Italian stroke centers. A total of 118 patients with acute ischemic stroke due to M1 segment middle cerebral artery occlusion will be randomized 1:1 in the emergency department to receive HDT15 or standard positioning (head-of-bed 0° to +30°) before and during MT. RESULTS: The primary end point is good collateral status (American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology grade 3–4), assessed on the first angiographic sequence during MT by a blinded imaging core laboratory. Secondary end points include feasibility (proportion maintaining HDT15, admission-to-MT time), safety (symptomatic intracranial hemorrhage, pneumonia, vomiting, neurological deterioration, vital signs), and efficacy (neurological improvement before MT, at 24 hours, and at 7 days or discharge, modified Rankin Scale score at 90 days). CONCLUSIONS: The DOWN-SUITE trial will provide evidence on the acute cerebrovascular effect of HDT15 in large vessel occlusion–acute ischemic stroke, potentially establishing a cost-effective, practice-changing intervention to improve collaterals for global stroke care. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06297863.

  • Open Access

    Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders

    by Zhao Zhang, Emma N. Somerville, Zih-Hua Fang, Lang Liu, Farnaz Asayesh, Jamil Ahmad, Saeid Amiri, Meron Teferra, Pauline Dodet, Isabelle Arnulf, et al.

    Isolated/idiopathic rapid-eye-movement (REM)-Sleep Behavior Disorder (iRBD) is characterized by dream enactment behaviors associated with loss of REM atonia. iRBD is in most cases a prodromal synucleinopathy, and emerging evidence suggests associations between RBD and other neurological and psychiatric conditions. In this study, we performed pathway-based polygenic risk score (PRS) and rare variant burden analyses to examine these potential associations. Pathway-specific PRS were constructed from genome-wide association study summary statistics of five neurodegenerative and seven psychiatric traits across 10 biologically relevant pathway categories, including a total of 279 pathways, in 1,573 iRBD cases and 16,022 controls from the International RBD Study Group and UK Biobank. Rare variant burden tests were performed in 1,264 iRBD cases and 2,581 controls. We identified multiple potential pathways indicating shared polygenic risk between RBD and both neurodegenerative and psychiatric disorders. Lewy body diseases and post-traumatic stress disorder had the most shared polygenic risk pathways in neurological and psychiatric disorders, respectively. Two pathways, the serotonin transport pathway and the chaperone-mediated autophagy pathway, showed the strongest association with iRBD, and gene-based rare variants analyses revealed five genes associated with iRBD: GBA1 , PLEKHM1 , LRP2 , P2RX1 , and HAP1. Subsequent analysis of these genes in Parkinson’s disease and dementia with Lewy bodies replicated several associations. Together, these findings provide novel insights into the shared genetic architecture underlying iRBD, neurodegenerative disorders, and psychiatric traits, with implications for early identification and mechanistic understanding.


  • Open Access

    Genome-wide association study of REM-sleep behaviour disorder identifies new risk loci

    by Emma N. Somerville, Lang Liu, Lynne Krohn, Farnaz Asayesh, Jamil Ahmad, Dan Spiegelman, Meron Teferra, Manuela Tan, Sheena Waters, Cristina Simonet, et al.

    Rapid-eye-movement (REM)-sleep behaviour disorder (RBD) can be a prodromal stage of α-synucleinopathies, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), and provides a unique opportunity to study and understand early neurodegeneration. Previous research on RBD has identified common risk loci in several PD and DLB genes, but the full extent of its genetic architecture and disease-specific associations remain unknown. In the present study, we aimed to identify novel loci associated with RBD by conducting an updated European RBD genome-wide association study (GWAS). We performed a meta-analysis using a previous RBD GWAS and newly genotyped RBD patients and controls, resulting in a total of 3,564 RBD cases and 140,393 controls analyzed. We further assessed the functional impact of new associations using fine-mapping and colocalization analyses with adult brain expression quantitative trait loci (eQTLs). To confirm if novel RBD loci are implicated in additional synucleinopathy phenotypes, we examined common variant associations in GWASs of PD risk, DLB risk, PD with RBD risk, PD age at onset, and various measures of progression. Additionally, rare variants were analyzed with the optimal sequence kernel association test (SKAT-O) in PD and DLB whole genome sequencing cohorts. Lastly, we analyzed known PD- and DLB-risk loci for associations with RBD. We identified RCOR1 as a novel risk locus for RBD, with fine-mapping suggesting the association to be driven by a variant in intron 2. Colocalization revealed no evidence for shared genetic signals with brain eQTLs, although this may reflect a lack of statistical power to detect an association. Common and rare variants in the RCOR1 locus were not associated with PD, DLB, and additional α-synucleinopathy phenotypes. We observed several PD and DLB risk loci to be associated with RBD, including MAPT , STK39 , and SIPA1L2 . The MAPT associated variant tags the protective H2 haplotype, consistent with previous findings in PD. Several SNCA variants previously associated with PD or DLB were also associated with RBD, but with differing directions of effect, highlighting the complex genetic landscape underlying α-synucleinopathy subtypes. This study identifies new RBD loci and strengthens our understanding of the genetic modifiers underlying RBD. Further replication and functional studies will be required to validate our findings and explore their biological implications.

  • Open Access

    Mid‐Regional Proadrenomedullin in Cerebrospinal Fluid Is a Reliable Diagnostic and Prognostic Marker for Acute Meningoencephalitis and Neurological Disorders

    by Francesco Janes, Paola Dalla Siega, Marco Comar, Matteo Furlani, Agnese Zanus Fortes, Daniela Visentini, Andrea Ripoli, Francesco Sbrana, Novella Carannante, Silvia Leonardi, et al.

    Objectives: Despite numerous pieces of evidence of its important role as a diagnostic and prognostic biomarker in infectious diseases and sepsis, adrenomedullin (ADM) was only poorly investigated in cerebrospinal fluid (CSF) in central nervous system (CNS) infections. In this multicentre retrospective study, we investigated ADM CSF concentrations in acute meningitis compared to other noninfectious neurological disorders. Methods: Since ADM is rapidly metabolised in vivo, the available diagnostic methods are designed to measure its cognate metabolite called mid‐regional proADM (MR‐proADM). We collected detailed clinical and laboratory data about 293 patients in whom MR‐proADM was measured in CSF and plasma as part of the diagnostic workup. Results: Patients were finally classified in CNS infection ( n = 59), other CNS disorders ( n = 190) and 14 disease controls, in which CNS infections and other definite disorders were excluded. Both cerebrospinal MR‐proADM levels and their CSF/blood ratio were significantly higher in CNS infections compared to the other two groups ( p < 0.001 and p < 0.037 respectively). CSF MR‐proADM resulted informative for patients' classification, furnishing a volume under the ROC surface of 0.513 [0.414–0.613], overcoming the 1/6 threshold value for undecidability. Threshold values of < 0.807 and > 1.590 nmol/L can differentiate controls from neurological disorders and neurological disorders from CNS infections respectively. Conclusions: We demonstrated significant upregulation of Adrenomedullin in CSF during infections compared to other neurological diseases and proposed preliminary thresholds of CSF MR‐proADM to be used in the diagnostic workup of acute CNS infections, to help with differential diagnosis and possibly guide targeted therapeutic interventions.


  • Top Cited Papers
    Open Access

    Association of the Timing and Type of Acute Symptomatic Seizures With Poststroke Epilepsy and Mortality

    by Kai Michael Schubert, Dominik Zieglgänsberger, Giulio Bicciato, Laura Abraira, Estevo Santamarina, José Álvarez-Sabín, Carolina Ferreira-Atuesta, Mira Katan, Lucia Sinka, Robert Terziev, et al.

    BACKGROUND: Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. METHODS: This multicenter cohort study included data from 9 centers between 2002 and 2018, with a final analysis in February 2024. The study included 4552 adults (2005 female; median age, 73 years) with ischemic stroke and no seizure history. Seizures were classified using International League Against Epilepsy definitions. We examined ASyS occurring within 7 days after stroke. The main outcomes were all-cause mortality and epilepsy. Validation of the updated SeLECT score (SeLECT-ASyS) was performed in 3 independent cohorts (Switzerland, Argentina, and Japan) collected between 2012 and 2024, including 74 adults with ASyS. RESULTS: The 10-year risk of poststroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (adjusted hazard ratio [aHR], 2.3 [95% CI, 1.3–4.0]; P =0.003) compared with later ASyS. Status epilepticus had the highest epilepsy risk (aHR, 9.6 [95% CI, 3.5–26.7]; P P P =0.004) and status epilepticus (aHR, 14.2 [95% CI, 3.5–58.8]; P P =0.02) and in the validation cohort (0.70 versus 0.50; P =0.18). CONCLUSIONS: ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.


  • Open Access

    Mid‐Regional Proadrenomedullin Can Be Reliably Measured in Cerebrospinal Fluid to Improve Diagnosis of Central Nervous System Diseases

    by Matteo Furlani, Daniela Visentini, Anna Rosa Cussigh, Fiorenza Pesente, Francesco Janes, Carlo Tascini, Francesco Curcio, Martina Fabris

    Background: Adrenomedullin (ADM) is a potent hormone‐like peptide rapidly induced by hypoxia and inflammatory cytokines in the early stages of sepsis. For this reason, the dosage of its more stable precursor fragment called mid‐regional (MR)‐proADM is currently recommended to assist in triaging patients in the emergency department. Since MR‐proADM dosage is currently only approved for use in plasma, we validated its dosage in cerebrospinal fluid (CSF) samples to improve the diagnosis of central nervous system (CNS) diseases.Methods: MR‐proADM concentrations were measured in samples using a fully automated platform (Brahms Kryptor Gold Analyzer, Thermo Scientific, Germany), applying the same analytical conditions in plasma and CSF samples, to finally set up an accurate laboratory protocol to validate its dosage in CSF.Results: MR‐proADM is highly stable in CSF samples stored at room temperature for up to 48 h, allowing it to be measured with confidence also in CSF samples that may be left on the bench for several hours. In addition, the repeatability and within‐laboratory precision of the MR‐proADM assay using CSF samples appeared equal to or better than those obtained by the manufacturer using plasma samples, allowing the use of this assay, with high precision, also for CSF samples.Conclusion: The reliable measure of MR‐proADM in CSF and the role of this molecule in CNS will allow its introduction in the diagnostic process of infectious, inflammatory, and degenerative neurological diseases.


  • Open Access

    Association of the timing and type of acute symptomatic seizures with post-stroke epilepsy and mortality

    by Kai Michael Schubert, Dominik Zieglgänsberger, Giulio Bicciato, Laura Abraira, Estevo Santamarina, José Álvarez-Sabín, Carolina Ferreira-Atuesta, Mira Katan, Lucia Sinka, Robert Terziev, et al.

    Background Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. Methods This multicenter cohort study included data from nine centers between 2002 and 2018, with final analysis in February 2024. The study included 4,552 adults (2,005 female; median age 73 years) with ischemic stroke and no seizure history. We examined ASyS occurring within seven days after stroke. Main outcomes were all-cause mortality and epilepsy. Validation in three separate cohorts included 74 adults with ASyS. Results The ten-year risk of post-stroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (aHR 2.3, 95% CI 1.3-4.0, p=0.003) compared to later ASyS. Status epilepticus had the highest epilepsy risk (aHR 9.6, 95% CI 3.5-26.7, pConclusions ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.


  • Open Access

    Brain Endothelial Cells Activate Neuroinflammatory Pathways in Response to Early Cerebral Small Vessel Disease (CSVD) Patients’ Plasma

    by Adriana Cifù, Francesco Janes, Catia Mio, Rossana Domenis, Maria Elena Pessa, Riccardo Garbo, Francesco Curcio, Mariarosaria Valente, Martina Fabris

    The pathogenesis of cerebral small vessel disease (CSVD) is largely unknown. Endothelial disfunction has been suggested as the turning point in CSVD development. In this study, we tested the effect of plasma from CSVD patients on human cerebral microvascular endothelial cells with the aim of describing the pattern of endothelial activation. Plasma samples from three groups of young subjects have been tested: PTs (subjects affected by early stage CSVD); CTRLs (control subjects without abnormalities at MRI scanning); BDs (blood donors). Human Brain Endothelial Cells 5i (HBEC5i) were treated with plasma and total RNA was extracted. RNAs were pooled to reduce gene expression-based variability and NGS analysis was performed. Differentially expressed genes were highlighted comparing PTs, CTRLs and BDs with HBEC5i untreated cells. No significantly altered pathway was evaluated in BD-related treatment. Regulation of p38 MAPK cascade (GO:1900744) was the only pathway altered in CTRL-related treatment. Indeed, 36 different biological processes turned out to be deregulated after PT treatment of HBEC5i, i.e., the cytokine-mediated signaling pathway (GO:0019221). Endothelial cells activate inflammatory pathways in response to stimuli from CSVD patients’ plasma, suggesting the pathogenetic role of neuroinflammation from the early asymptomatic phases of cerebrovascular disease.


  • Open Access

    Brain Endothelial Cells Activate Neuroinflammatory Pathways in Response to Early Cerebral Small Vessel Disease (CSVD) Patients’ Plasma

    by Adriana Cifù, Francesco Janes, Catia Mio, Rossana Domenis, Maria Elena Pessa, Riccardo Garbo, Francesco Curcio, Mariarosaria Valente, Martina Fabris

    The pathogenesis of Cerebral Small Vessel Disease (CSVD) is largely unknown. Endothelial disfunction has been suggested as the turning point in CSVD development. In this study we tested the effect of plasma from CSVD patients on human cerebral microvascular endothelial cells with the aim of describing the pattern of endothelial activation. Plasma samples from 3 groups of young subjects have been tested: PTs (subjects affected by early stage CSVD); CTRLs (control subjects without abnormalities at MRI scanning); BDs (blood donors). Human Brain Endothelial Cells 5i (HBEC5i) were treated with plasma and total RNA was extracted. RNAs were pooled to reduce gene expression-based variability and NGS analysis was performed. Differentially expressed genes were highlighted comparing PTs, CTRLs and BDs with HBEC5i untreated cells. No significantly altered pathway was evaluated in BD related treatment. Regulation of p38 MAPK cascade (GO:1900744) was the solely pathway altered in CTRLs related treatment. Indeed, 36 different biological processes turned out to be deregulated after PTs treatment of HBEC5i, i.e., the cytokine-mediated signaling pathway (GO:0019221). Endothelial cells activate inflammatory pathways in response to stimuli from CSVD patients’ plasma, suggesting the pathogenetic role of neuroinflammation from the early asymptomatic phases of cerebrovascular disease.